Publications by authors named "Laurie Pearson"
Hodgkin lymphoma (HL) affects older and younger patients and includes multiple options for initial treatment. We sought to examine the decision processes of practicing oncologists caring for patients with newly diagnosed HL. Through semi-structured interviews, we explored their perspectives about treatment decisions.
View Article and Find Full Text PDFMyeloid sarcoma (MS) is a rare extramedullary manifestation of acute myelogenous leukemia (AML). The mass is composed of primitive myeloid cells that can occur in a variety of organs, most commonly the skin, lymph nodes, GI tract, bone, breast, and CNS. Involvement of the genitourinary tract is rare.
View Article and Find Full Text PDFArticle Synopsis
- - Elderly CLL patients (>75 years) experience more toxicity from ibrutinib compared to younger patients, but the safety of venetoclax in older patients is unclear.
- - This study analyzes safety and efficacy data from 342 CLL patients aged 75 and older versus those under 75, focusing on non-trial treatment settings.
- - Results indicate that venetoclax is equally effective and safe for elderly patients, many of whom have already been treated with ibrutinib and have limited treatment options.
Article Synopsis
- - The study investigated the occurrence of tumor lysis syndrome (TLS) and adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax outside of clinical trials, involving 297 patients from various treatment centers.
- - Among the findings, only 2.7% of patients experienced clinical TLS and 5.7% had laboratory TLS, with major adverse events including neutropenia and thrombocytopenia being notable.
- - The results suggest a need for better TLS risk grading and prophylaxis adherence in routine practice, despite progression-free survival being unaffected by dose modifications in this patient group.